Catalent completes clinical production of opioid addiction therapeutic developed by Bridge using Zydis technology and gets exclusive license ahead of regulatory filing.
Sharp’s electronic label for drug packaging can be updated again and again, saving time and costs whilst also improving patient engagement during clinical trials.
‘Talk to your CDMO early’ is the advice BioConnection gives to developers of biopharmaceuticals, suggesting that they make a reservation to ensure availability.
Catalent to invest $9m in the building of an early-stage clinical supply facility in San Diego, due to open in the summer of 2020, to integrate its CDMO business.
Samsung Biologics and UCB agree to an additional drug substance manufacturing deal to produce an anti-tau candidate currently in Phase I clinical trials to treat progressive supranuclear palsy.
Zosano completes site qualification batches for its subcutaneous investigational migraine treatment and readies itself for NDA submission by the end of year.
Marken executive says there is no such thing as a perfect clinical trial supply chain but with strategic planning and innovations there are opportunities to better serve the research industry.
Sharp invests $650,000 in its IRT solution to ensure proper supply allocations to support clinical trials and reduce costly overproduction for sponsors.
Catalent’s existing clinical packaging facility in Shanghai is nearing the end of its expansion, ready to meet the needs of the growing Asia-Pacific region.
